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Abstract
Background: Spinal muscular atrophy (SMA) is the most common pan-ethnic cause of early childhood death due
to mutations in a single gene, SMN1. Most chromosome 5 homologs have a functional gene and dysfunctional
copy, SMN2, with a single synonymous base substitution that results in faulty RNA splicing. However, the copy
number of SMN1 and SMN2 is highly variable, and one in 60 adults worldwide are SMA carriers. Although
population-wide screening is recommended, current SMA carrier tests have not been incorporated into targeted
gene panels.
Methods: Here we describe a novel computational protocol for determining SMA carrier status based solely on
individual exome data. Our method utilizes a Bayesian hierarchical model to quantify an individual’s carrier
probability given only his or her SMN1 and SMN2 reads at six loci of interest.
Results: We find complete concordance with results obtained with the current qPCR-based testing standard in
known SMA carriers and affecteds. We applied our protocol to the phase 3 cohort of the 1,000 Genomes Project
and found carrier frequencies in multiple populations consistent with the present literature.
Conclusion: Our process is a convenient, robust alternative to qPCR, which can easily be integrated into the
analysis of large multi-gene NGS carrier screens.
Keywords: 1000 Genomes Project, Carrier testing, DNA-seq, Exome-seq, Genetic testing, Next-generation
sequencing (NGS), SMN1, SMN2, Spinal muscular atrophy (SMA)
Background
Spinal muscular atrophy (SMA) is a common autosomal
recessive disorder affecting approximately 1/10,000 live
births [1]. The disease results from the degeneration of
spinal cord motor neurons, which leads to the progressive
weakness and deterioration of skeletal muscle, and even-
tually paralysis and death [2]. SMA is categorized into four
clinical types based on disease manifestations and age of
onset [3]. Type I (OMIM: 253300) patients have severe
muscle weakness within the first three months of life;
death usually occurs within the first two years. Patients
with Type II SMA (OMIM: 253550) are able to sit, but
cannot stand or walk; they typically survive beyond four
years. Type III SMA (OMIM: 253400) is a milder form of
SMA; these patients are diagnosed later in their youth and
can walk unaided [2, 3]. The mildest adult-onset form of
SMA (Type IV, OMIM: 271150) is found in patients who
can walk into adulthood [2].
All autosomal recessive forms of SMA disease are
caused by variant forms of the SMN locus on chromo-
some 5 (chr5), which ordinarily contains two nearly
identical copies of a gene encoding the survival of motor
neuron gene product [4]. The two gene copies, referred
to as SMN1 and SMN2, were derived through a recent
duplication event along the human lineage (Fig. 1) [5].
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They have identical exon-intron organizations and the
potential for the same gene product.
SMN1 and SMN2 are typically distinguished by a
handful of single nucleotide differences, only one of
which has an impact on the corresponding polypeptide
[2, 5–9]. This single functional difference occurs at the
sixth base of the eighth exon (referred to traditionally as
exon 7) (840 C > T). The SMN2 base (T) is synonymous
in terms of amino acid coding, but causes a rate of
exon-skipping of 50-90 % (depending on the tissue ana-
lyzed) and corresponding reduction of gene functionality
(Fig. 1b, Additional file 1: Figure S1a) [10–13].
Variant forms of the SMN locus are produced at a fre-
quency of approximately 1 in 10,000 by intergenic meiotic
recombination between homologous regions within and
around SMN1 and SMN2 (Fig. 1c). Unequal crossing-over
generates two chromosomal products containing one gene
or three genes, respectively. Depending on the location of
the cross-over event, the single gene chromosome will
carry either SMN1 or SMN2, and the three gene chromo-
some will have a 1:2 or 2:1 SMN1:SMN2 ratio (Fig. 1d).
Alternatively, at a much lower frequency, heteroduplex
formation across the gene-defining SMN location will
resolve without crossing over, leading to gene conversion.
Gene conversion does not alter copy number but can
result in two copies of either SMN1 or SMN2. Due to the
high degree of repetitive sequence in SMN1, intragenic re-
combination is also quite likely and can lead to deleterious
variations [14].
As a result of recombination in the SMN locus, a large
degree of variability in SMN1 and SMN2 copy number
exists in the global human population [14]. Up to 15 %
of individuals lack SMN2 completely, while others can
have three or more copies of this gene [10, 14–17].
However, all variant chromosomes formed by intergenic
recombination must carry at least one SMN gene that
may be SMN1 or SMN2.
Carrier frequency for SMA ranges from about 1/47 in
European populations to 1/72 in African Americans
[10, 18, 19]. Approximately 95 % of SMA cases are a con-
sequence of SMN1 gene transformation by unequal cross-
ing over or gene conversion [20]. Most of the remaining
SMA affected patients are compound heterozygotes with
intragenic mutations in their single remaining copy of
SMN1 [4, 10, 15].
Prompted by the severity of SMA and its high pan-
ethnic incidence rate, the American College of Medical





Fig. 1 Evolution of the human SMN locus. a. The human SMN1 and SMN2 genes were derived by duplication of a proto-SMN gene after
the human-chimpanzee split. The yellow bar represents the only functional base change that distinguishes SMN2 from SMN1 (on chromosome 5 at
position 69,372,353 in the GRCh37/hg19 reference genome) which is signified on the canonical transcript position as c.840C > T. The copy number of
each gene on a single chromosome is indicated in the bracket and colon formulation [SMN1:SMN2]. A canonical SMN chromosomal locus consists of
one copy of each gene in the centromere-telomere order SMN2-SMN1. A canonical homozygous genotype is represented as [1:1]/[1:1]. b. Comparison
of SMN1 and SMN2 sequences on either side of the gene-defining c.840C > T base difference. c. Three categories of interlocus homologous
recombination between SMN1 and SMN2 generate copy number variants of the SMN locus. 1. Recombination and exchange on the centromeric side
of the SMN2-defining base; 2. recombination and exchange on the centromeric side of the SMN2-defining base; 3. interlocus gene conversion across
the SMN2-defining base region, indicated with the double-arrowed line. d. Each recombination event produces two variant SMN chromosome types
which are cross-referenced from panel c. Variant chromosomes are ordered by total SMN copy number
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SMA carrier testing in order to identify couples at
risk of conceiving an SMA affected child [21]. The
conventional SMA screening protocol involves some form
of quantitative polymerase chain reaction (qPCR) directly,
or in combination with multiplex ligation-dependent
probe amplification (MLPA), TaqMan, restriction frag-
ment length polymorphism, denaturing high-performance
liquid chromatography, or direct (Sanger) sequencing
[15, 22–27] (see [28] for a review). qPCR primers are
designed specifically to amplify segments of exon 7 con-
taining the SMN1-defining sequence. The copy number of
SMN1 is calculated by comparing its cycle threshold
directly to that of a control gene(s). One of the most ro-
bust methods to detect SMA carriers is MLPA, a qPCR
based method that utilizes fragment fluorescence intensity
to determine SMN1 and SMN2 copy number [23, 29, 30].
While existing qPCR approaches are accurate on a
case-by-case basis, none of the current processes can be
incorporated into cost-effective NGS screens for the
simultaneous detection of carrier status at hundreds of
genes [31]. In this paper we present a novel Bayesian
analysis protocol to determine the probability that an in-
dividual is an SMA carrier given only his or her sequen-
cing coverage at a few sites of interest. We applied our
technique to known SMA carriers and over fifty samples
with unknown genotypes. Our NGS method accurately
predicted the status of known carriers, and provides out-
put as a continuous likelihood, rather than a binary scale,
for each individual. We applied our algorithm to deter-
mine the carrier status of individuals from the Phase 3
release of the 1000 Genomes Project [32] to demonstrate
its effectiveness in a large diverse sequencing study where
qPCR is not a reasonable alternative. Our statistical ap-
proach is a useful method for determining SMA carrier
status from only DNA-sequencing data and should be part
of a large NGS carrier-testing platform.
Methods
Sample collection and initial processing
We collected semen or saliva samples from volunteers.
We anonymized sample names to conceal personal iden-
tification information.
Saliva samples were collected with the Oragene Dx
(ODG-510) collection kit (DNA Genotek, Kanata On-
tario, Canada). Genomic DNA was extracted from saliva
samples using the prepIT L2P (DNA Genotek, Kanata
Ontario, Canada) reagents per the manufacturer’s in-
structions. Semen samples were immediately cryopre-
served at −190 °C after collection. DNA was extracted
from the semen samples using the MasterPure Complete
DNA & RNA Isolation Kit (Epicenter, Madison WI, USA)
according to the manufacturer’s specifications. Genomic
DNA from both saliva and semen were re-purified using
the Genomic DNA Clean and Concentrator-5 Kit (Zymo
Research, Irvine CA, USA) according to the manufac-
turer’s protocol.
The integrity for both the saliva- and semen-extracted
DNA was verified by electrophoresis in 2 % agarose gels.
DNA concentration and quality were measured with the
Qubit dsDNA HS Assay kit (Life Technologies, Grand
Island NY, USA) and the NanoDrop 8000 spectropho-
tometer (NanoDrop, Wilmington DE, USA). NanoDrop
OD ratios above 1.7 for A260/280 and above 1.7 for
A260/230 indicate high purity of samples. Final DNA
concentration for each sample was adjusted to 4 μg/ml,
a sufficient amount to obtain at least 2 μg of genomic
DNA per sample. Final DNA samples were aliquoted
and stored at −20 °C prior to use. Genomic DNA sam-
ples that did not meet OD ratios above 1.7 and had
DNA content below 100ng were re-collected or removed
from NGS processing.
Additionally, 2,532 aligned BAM files from the Phase 3
of the 1000 Genomes Project (1KG3) were downloaded
for subsequent processing (ftp://ftp-trace.ncbi.nih.gov/
1000genomes/ftp/) [32]. We removed 31 samples that
were classified as related by the 1000 Genomes Project
Consortium.
Ethics, consent and permissions
The GenePeeks Research Ethics Committee approved
research use of saliva and semen samples. All samples
were previously collected from volunteers consenting to
use their sample and derivative information for add-
itional genetic testing or future research. We obtained
written consent from all participants.
Consent to publish
Each volunteer participant gave written consent to pub-
lish his or her individual data.
Sequencing
The Illumina TruSight Inherited Disease panel (Illumina,
San Diego CA, USA) was chosen to sequence samples.
The panel contains 552 disease-associated genes, includ-
ing SMN1 and SMN2. A total of 150 ng of genomic DNA
collected from saliva, semen, and Coriell Institute DNA
samples were prepared with the panel according to the
manufacturer’s protocol. Pooled libraries were size se-
lected on the Pippin Prep (Sage Sciences, Beverly MA,
USA) for 300-700bp and were sequenced on the Illumina
MiSeq at 2x 300 cycles.
Bioinformatics processing
We used the Burrows-Wheeler Alignment tool (BWA
MEM) [33] to align the sequence reads to the human
reference genome, GRCh37/hg19 (downloaded from the
Genome Analysis Toolkit (GATK) version 2.8), creating
a single aligned BAM file for each individual saliva,
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sperm, and Coriell sample. Potential PCR duplicate reads
were marked by running the aligned subject data
through the Picard MarkDuplicates tool (http://broadin-
stitute.github.io/picard/). We then performed local re-
alignment for each sample by using the GATK
IndelRealigner tool followed by recalibrating base qual-
ities using the GATK BaseRecalibration tool, both ac-
cording to GATK recommended best practices [34].
The average gene coverage for individual genes was
determined for each saliva, sperm, Coriell, and 1KG3
sample by running the resulting BAM files through
GATK’s DepthOfCoverage analysis tool. Total coverage
for three SMN1 loci on chromosome 5 (chr5:70,247,724,
chr5:70,247,773, and chr5:70,247,921) and three SMN2
loci (chr5:69,372,304, chr5:69,372,353, and chr5:69,37
2,501) was parsed from the output data from the
DepthOfCoverage tool.
MLPA
Copy number status was determined by Multiplex
ligation-dependent probe amplification (MLPA) [23].
We used 200ng per sample reaction of genomic DNA
from human saliva, semen, and Coriell Institute DNA
samples with the SALSA MLPA SMA P060 probe mix
kit (MRC-Holland, Netherlands) according to the manu-
facturer’s protocol (Additional file 2: Table S1). The
MLPA PCR products were separated and captured for
probe fluorescence intensity by capillary electrophoresis
on the ABI3730XL (Applied Biosystems, Foster City CA,
USA). Raw data files were analyzed for copy number sta-
tus on the Coffaylser. NET software (MRC-Holland,
Netherlands). Two Coriell Institute samples with 1 copy
of SMN1 and 2 copies of SMN2 were chosen as positive
controls for MLPA. We chose three reference controls
that have 2 copies of SMN1 and 2 copies of SMN2 from
a previous MLPA experiment using SD019 Reference
DNA (MRC-Holland, Netherlands) as the SMA normal
reference control. Samples were run in duplicate; final
SMN1 to reference ratios reported in the main text and
tables represent averages of these values.
SMN1 reads at loci of interest
We consider N subjects. Let Dbi = 0, 1, 2, …,rbi be the
number of reads that align to SMN1 in the ith subject (i =
1,2,…,N) at chr5:70,247,773, where rbi is the total number
of reads aligned to the SMN1 region (chr5:70,247,773) and
the analogous SMN2 region (chr5:69,372,353). Note that
these two loci, denoted with the letter ‘b’ and located in
exon 7 of their respective genes, correspond to the only
coding differences between SMN1 and SMN2. We also ex-
amined two intronic loci on either side of exon 7 symbol-
ized by a (chr5:70,247,724 in SMN1 and chr5:69,372,304
in SMN2) and c (chr5:70,247,921 in SMN1 and chr5:69
,372,501 in SMN2).
We use πi to represent the probability that a SMN1 or
SMN2 (denoted as SMN) read is actually from SMN1 in
the ith subject. We define π^bi as the observed proportion
of SMN reads that align to SMN1 in exon 7 (i.e., π^bi ¼ Dbi
=rbi), and calculated π^ai and π^ci in a parallel manner. Our
observed proportion of SMN1 reads is π^ i ¼ Di=ri , where,
for most samples, Di is the total number of SMN1 reads
and ri is the total number of SMN reads at our three loci
of interest (i.e., Di =Dai +Dbi +Dci and ri = rai + rbi + rci). If
π^bi−π^aij j > ∈ or π^bi−π^cij j > ∈ , for some ∈ > 0 (∈ = 0.10,
here), then the so-called ∈ condition is not met and we let
Di =Dbi and ri = rbi.
Scaled SMN1 reads
To further account for SMN1 copy number, we consid-
ered K “housekeeping” or control genes (k = 1, 2,…, K)
and calculate zki = (c1i + c2i)/Hki, where c1i is the average
coverage for the SMN1 gene region, c2i is the average
coverage for SMN2, and Hki is the average coverage for
gene k in the ith subject.
For each person, we calculated a weighted average
of the coverage of SMN1 to our K housekeeping
genes: θ^ i ¼
XK
k¼1zki=zk




is the total number of subjects. For conservatism, any
values of θ^ i > 1:0 are set to 1.0 so that our scaling
factor has a ceiling of 1.00 (i.e., θ^ i∈ 0; 1½ ).
Selecting housekeeping genes representative of
genome-wide copy-number is nontrivial. We wanted
to only include genes that have sufficiently high
coverage in the majority of subjects. Genes with low
coverage (lower than the 5th percentile in at least
10 % of subjects) were not considered. Those that
passed this coverage filter were then selected for one of
two properties: (1) low variability in average coverage
across all samples or (2) low variability in zki across all
samples. To account for differences in scale, we used the
coefficient of variation across all samples ( θ^=μ^ ) to rank
the variability of each gene. We chose the top ten genes
according to properties (1) and (2) for a total of K = 20
control genes. Unlike other copy number determining
algorithms, our housekeeping genes do not necessarily
need to be 2-copy across all samples, but they do need
consistent coverage relative to SMN.
We use θ^ i to scale our observed SMN1 reads to Di′ ¼ θ^ i
Di and let π^ i
′ ¼ Di′=ri represent our scaled estimate of πi.
In this way, we account for the number of SMN reads rela-
tive to low variability regions.
Bayesian hierarchical model
Assuming that we align to either a SMN1 or SMN2 at
our polymorphic sites, the (scaled) number of SMN1
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reads is binomially distributed: Di′ ¼ θ^Di∼Bin ri;πið Þ ,
where πi is the probability that a SMN read is
actually from SMN1 in the ith subject. Thus,





distribution allows us to model the reads in our dataset;
however, we are more interested in making inference
about πi. In particular, we want to know
P subject is a carrierjsequencing datað Þ
¼ Pðratio of SMN1 reads to SMN2 reads is 1 : 2; 1 : 3; etc:Þ
¼ P proportion of SMN1 reads is 1=3; 1=4; etc:ð Þ
¼ P πi≤ 1=3ð jDi′; riÞ:
To this end, we use a Bayesian hierarchical model and
assume a (conjugate) prior for πi: πi ∼ Beta(α, β). Thus,
the posterior distribution for πi is also a beta
distribution:
πi Di




We calculate P(πi ≤ 1/3|Di′, ri) directly via the cumula-
tive distribution function of our posterior beta distribu-
tion. In order to conservatively capture all potential
carriers, we allow a 5 % “Type I error” and present car-
rier probability results calculated As P(πi ≤ 0.38|Di′, ri)
rather than P(πi ≤ 1/3|Di′, ri). We considered both a
uniform prior (α = β = 1) and Jeffreys noninformative
prior (α = β =1/2).
This method can easily be extended to the case where
our loci are not biallelic with a multinomial-Dirichlet
Bayesian hierarchical model.
Sample categorization
We classified each sample into one of three categories
based on its corresponding credible interval. Individuals
with 95 % credible intervals for π entirely below 0.38 are
“likely” carriers; those with intervals that span 0.38 are
“possibly” carriers. All others are “unlikely” carriers. Our
posterior carrier probability (and corresponding credible
intervals) is calculated to determine the probability that
an individual has a true π ≤ 0.38 given the data. Unlike
frequentist confidence intervals, there is a 95 % chance
that the true π is in the bounds of the given 95 % cred-
ible interval. Thus, if an individual’s credible interval
contains 0.38, it is literally possible that he or she is an
SMA carrier. Note that because our final posterior car-
rier probability is continuous on the [0,1] scale, this
metric is more meaningful than the discrete “likely”,
“possible”, and “unlikely” carrier categorizations. We rec-
ommend that clinical users of our method verify results
by MLPA for “possible” carriers in the clinic.
Theoretical results
In theory, the copy number ratio of SMN1, SMN2, and
each housekeeping region are consistent among all indi-
viduals with two copies of SMN1, SMN2. Thus, normal
SMA copy number individuals will have a zki=zk ¼ 1
and a calculated weighted average θ^ i ¼ 1 (Additional file
3: Table S2). Those with fewer than two copies of SMN1
and/or SMN2 will have θ^ i < 1 (Additional file 3: Table S2).
Observed carrier frequencies were taken from [14]
and [16].
To determine the relationship between coverage and
carrier probability, we obtained 1,000 random realiza-
tions of D|r,π and calculated the average P(π ≤ 0.38|D, r)
for a given value of r and π.
Results
Volunteer, Coriell, and 1000 Genomes Samples sequenced
for carrier testing
To determine the accuracy of our method, we collected
and sequenced DNA from 56 healthy volunteers and 15
samples from the Coriell Institute. The volunteer samples
were collected via saliva (nsaliva = 47) or semen (nsemen = 7);
there was no difference in their average sequencing cover-
age (p-value = 0.195). The Coriell cohort included nine
positive controls: five individuals affected with SMA and
four SMA carriers. We also analyzed six diagnosed non-
SMA diseased control Coriell samples: two normal healthy
controls (NHC), two with amyotrophic lateral sclerosis
(ALS), one with Duchenne muscular dystrophy (DMD),
and one with X-linked SMA (SMAX1). While four of these
individuals are affected with a neuromuscular disease
having a notable genetic component, they are only as likely
as a randomly selected individual to be an SMA carrier.
Additionally, we processed the raw sequencing data from
2,501 unrelated members of the 1000 Genomes Project
Phase 3 (1KG3) release; the carrier status of these samples
was completely unknown.
Novel sequencing-based SMA carrier detection method
We developed a Bayesian hierarchical model to quantify
the probability that an individual has at most one copy of
SMN1 given his or her distribution of aligned DNA-seq
reads to SMN1 at three nucleotide differences that distin-
guish canonical SMN1 and SMN2 (Methods, Additional
file 1: Figure S1b). Briefly, we assume that the number of
reads aligning to the loci in SMN1 and SMN2 can be
modeled by a binomial distribution with a fixed number
of total reads and probability, π, that a read aligned to this
region is actually from SMN1. We found almost no differ-
ence between the outcomes of two uninformative priors
for our model (Additional file 4: Figure S2) and proceeded
with Jeffreys conjugate prior.
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Given our sequencing data and prior, the posterior of
our parameter of interest (π) follows a closed-form beta
distribution, making corresponding carrier probabilities
computationally easy to calculate (Methods). The chance
of being a carrier is inversely proportional to the number
of reads aligned to SMN1; subjects with an observed es-
timate of π (denoted as π^ ) less than 1/3 have high car-
rier probabilities (Additional file 3: Table S2).
We simulated 1,000 individuals at three carrier and
five non-carrier SMN1:SMN2 copy number ratios (0, 1:3,
& 1:2, and 2:3, 1:1, 2:1, 3:1, & 1:0, respectively) with vari-
ous SMN total reads (1 to 3,000) and calculated their
average carrier probabilities with our method (Methods).
For hypothetical carriers (π ≤ 1/3), a minimum of 350
SMN reads are needed to obtain an average carrier prob-
ability of 0.90 (i.e., 90 % sensitivity; Fig. 2). However,
even with 150 SMN reads, the average posterior probabil-
ity among simulated carriers is at least 0.80 (Fig. 2b). With
just 10 reads aligning to our loci of interest in SMN, SMA
affected individuals (i.e., SMN1:SMN2 = 0, π = 0) can be
assigned an average probability of at least 0.998 for having
one or fewer SMN1 gene copies. Non-carriers with at least
a 1:1 SMN1:SMN2 ratio (π ≥½) have an average carrier
probability less than 0.10 (90 % sensitivity) with more than
75 reads, and 0.001 (99.9 % sensitivity) with more than
200 reads. Simulated individuals without any SMN2 copies
have an average carrier probability less than 10−5 with just
10 reads. Non-carrier subjects with a 2:3 SMN1:SMN2
ratio (π = 2/5), require at least 1,000 reads for a carrier
probability less than 0.20 (Fig. 2a).
For most subjects (95.8 % in the volunteer and Coriell
cohort and 74.3 % in 1KG3 set), we pooled data ob-
tained from all three canonical SMN1-defining base
positions. However, if the proportion of reads that
aligned to SMN1 at either of our two intronic sites
differed from the one in exon 7 by more than 10 %,
we calculated our observed proportion based only on
the reads aligning to the unique site in exon 7. The
three volunteer and 642 1KG3 subjects for whom this
is the case have significantly lower coverage in this
region of the genome compared to those samples that
do not fail the 10 % criterion (p-values = 5.46 x 10−6
and 3.45 x 10−8, respectively).
Scaled SMN1 reads
Because the DNA sequences of SMN1 and SMN2 are so
similar, and their copy numbers so variable, we extended
our method to compare the total SMN coverage in each
sample to that of several “housekeeping” genes. These
genes were selected based on their high coverage and
low variability in the majority of subjects (Methods). In-
dividuals with a canonical genotype (Fig. 1a) will have
one read aligning to SMN1 and SMN2 (4 total copies)
for every reference gene (2 copies). We account for the
number of SMN copies with a weighted average of the
SMN to housekeeping genes ratio (our “scaling factor”),
which is capped at 1.00. We multiply the number of
reads aligning to our loci of interest in SMN1 by this
scaling factor, and use these values to estimate the scaled
probability that a read aligned to this region is actually
from SMN1 (denoted as π^ ′).
We examined 20 distinct housekeeping genes in the
volunteer, Coriell (Additional file 5: Table S3) and 1KG3
samples (Additional file 6: Table S4). Only three genes
(FASTKD2, RAB3GAP1, and SLC35D1) were included
on both lists.
The estimate of π for the majority of samples was not
drastically affected by the scaling of reads (Additional file
7: Table S5, Additional file 8: Table S6, Additional file 9:
Figure S3). About half of the volunteer and Coriell sam-
ples (54.9 %) and of 1KG3 samples (52.1 %) have scaling
factors not equal to 1.0, with average values of 0.84 (Add-
itional file 7: Table S5, Additional file 8: Table S6). The sal-
iva and semen volunteer samples do not have different
average scaling factors (p-value = 0.137). The estimates of
π before and after scaling are very tightly correlated for
both cohorts (Spearman rank correlation ≥ 0.96, p-values
< 2.2 x 10−16). Further, only three volunteer and Coriell
samples (A23, C15, and NA03185) and 30 1KG3 samples
had carrier probabilities that differed by more than 0.1
due to scaling (Additional file 7: Table S5, Additional file
8: Table S6).
Sequencing method accurately classifies SMA carriers and
non-carriers
The distribution of π^ ′ is multimodal among the healthy
volunteer and Coriell subjects, with the highest peak near
0.5, corresponding to an equal copy number for SMN1
and SMN2 (Additional file 10: Figure S4a). There is no dif-
ference in the average π^ ′ values for the saliva versus sperm
samples (p-value = 0.507). The six subjects with values of
π^ ′ at or near 1.0 have a homozygous loss of SMN2, and
the five with π^ ′ values at or near 0.0 have a homozygous
loss of SMN1 (i.e., they are affected with SMA).
As expected, the relationship between π^ ′ and the pos-
terior probability that π is less than 0.38 given the data
(i.e., the carrier probability) has a reverse sigmoidal
shape (Fig. 3a). Subjects with low values for π^ ′ have very
high carrier probabilities, and vise-versa. Individuals with
95 % credible intervals for π that include 0.38 are “pos-
sible” carriers, with intermediate posterior probabilities
(Fig. 3b). Subjects with high coverage at our SMN gene-
defining base positions have very narrow credible inter-
vals (Additional file 7: Table S5).
One Coriell subject (NA03815), who fathered two af-
fected offspring, had an SMN1 to SMN2 reads ratio
close to 1 : 1 π^ ¼ 0:53ð Þ . Without scaling, he has a very
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Fig. 2 Simulation results of the number of SMN reads versus the posterior carrier probability for various levels of π for a maximum of (a) 3,000
and (b) 350 reads. Each point represents the average across 1,000 permutations. The red, blue, and green lines correspond to values of π less
than or equal to 1/3 correspond to true carriers
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low carrier probability (2.14 x 10−92). However, after
scaling, the proportion of his SMN reads attributable to
SMN1 is 0.26, resulting in a final carrier probability of
1.0 (Additional file 7: Table S5). A volunteer’s saliva sam-
ple (A23) had a similar pattern (initial carrier probability
of 9.00 x 10−10, final carrier probability of 0.83). The
most parsimonious explanation for these two cases is
that both individuals have a single SMN gene with two
recombination-derived alleles (represented as r1 and r3
in Fig. 1d). Thus, in formal genetic terms, these two in-
dividuals are heterozygous for a single base mutation in
SMN1 (i.e., SMN2).
In addition to NA03815, all of the known SMA car-
riers and affecteds have a carrier probability of 1.0 ac-
cording to our computational protocol (Additional file 7:
Table S5). The five affected SMA samples have π^ ′ values
near 0.0, and 95 % credible intervals for π with upper
bounds below 0.02 (Additional file 7: Table S5, Fig. 3b).
The four unaffected SMA carriers have 95 % credible in-
tervals for π with upper bounds below 0.33. One of our
non-SMA diseased control Coriell samples (NA11067),
is a male with SMAX1 (OMIM: 313200), an X-linked
version of SMA caused by an expansion in AR (see [35]
for a review); he also has an SMA carrier probability of
1:0 π^ ′ ¼ 0:32ð Þ . The maximum carrier probability of the
five other non-SMA diseased control Coriell samples
(who were NHCs or affected with DMD or ALS) is 3.35
X 10−6 (Additional file 7: Table S5).
Among the volunteer samples, one (C21) is a clear
carrier (π^ ′ = 0.30, carrier probability = 1.0). Three others
(A23, C15, and M21) are possible SMA carriers, with
posterior probabilities above 0.10 (Additional file 7:
Table S5).
Sequencing carrier status replicated by MLPA
We used MLPA to determine the carrier status for a
subset of our volunteer and Coriell samples. Of the 24
volunteer samples that were not chosen for MLPA, eight
had insufficient DNA quantities (≤495ng of DNA, a
minimum of 600ng was needed for MLPA) after using
these samples for DNA-seq. We are confident that an
additional 16 individuals have at least two copies of
SMN1 due to their high coverage (average SMN reads =
1352.13, range = [372, 2764]) and values for π^ ′ (average
π^ ′ = 0.539, range = [0.460, 0.680]) which led to their
exclusion from the MLPA analysis. None of these sam-
ples were likely carriers (carrier probability ≤ 2.86 X10−8;
Additional file 7: Table S5).
We found a strong correlation between the sequencing-
based and MLPA carrier statuses for each sample (Fig. 4,
Additional file 7: Table S5). Eleven of the twelve samples
that are carriers by the MLPA method (SMN1:reference <
0.7) have a carrier probability of 1.0, and the twelfth sam-
ple (A23) has a very high carrier probability (0.83) based
on our sequencing method (Additional file 7: Table S5;
Fig. 4). Further, only two of the 35 non-carriers (MLPA
SMN1:reference > 0.7) have carrier probabilities above
7.51 X 10−6 based on their sequencing data; these two
have low posterior probabilities of 0.25 (C15) and 0.11
(M21) (Additional file 7: Table S5; Fig. 4). The SMAX1
Coriell subject (NA11067) is a carrier based on his MLPA
result (SMN1:reference = 0.52).
Proportion of 1KG3 carriers closely matches
corresponding population
Consistent with the published frequencies for SMN1 and
SMN2 copy numbers [15, 17] and the results for the vol-
unteer and Coriell subjects, the multimodal distribution
of the ratio of SMN1 to SMN reads has peaks near the
three most common genotypes: 0.50 (corresponding to a
2:2 SMN1:SMN2 ratio), 0.67 (2:1 SMN1:SMN2 ratio),
and 1.0 (2:0, 3:0, or 4:0 SMN1:SMN2 ratio) (Additional
file 10: Figure S4b).
Based on our ternary groupings, there are 16 1KG3 sub-
jects who are high-probability carriers, 109 possible car-
riers, and 2,376 unlikely carriers (Fig. 5, Additional file 8:
Table S6, Additional file 11: Figure S5). The possible car-
riers had significantly lower coverage than the other 2,392
individuals in this cohort (average total coverage of 248.0
and 486.9, respectively, p-value = 9.59 X 10 −15).
In order to compare the carrier frequency in five
1KG3 superpopulations to those from a recent large
meta-analysis [14], we reclassified all subjects into binary
“carrier” and “non-carrier” divisions. We assigned all
subjects who are more likely than not to be carriers as
“carriers” (posterior probability >0.5), and all others as
“non-carriers”. Even though some of these subjects have
lower than optimal coverage, their posterior probabilities
take into account this low coverage and corresponding
uncertainty are thus still interpretable.
(See figure on previous page.)
Fig. 3 Results for volunteer and Coriell samples. a. Estimate of the scaled proportion of SMN reads that are from SMN1 versus the carrier probability for
each subject. The carrier probability can be interpreted as the probability that a point on the x-axis falls to the left of the vertical line at 0.38. Samples
where few SMN reads align to SMN1 are likely SMA carriers, whereas those with a high proportion of SMN1 reads are unlikely SMA carriers. b. 95 %
Posterior (credible) intervals for π are plotted for each subject. In both (a) and (b), subjects that did not meet our 10 % threshold across our three loci
are labeled with stars. Note that their intervals in (b) are much wider due to their low coverage. Subjects in both plots are colored red if their credible
interval is entirely below the 0.38 cutoff (vertical blue line) and orange if their interval overlaps with 0.38
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Fig. 4 (See legend on next page.)
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We found no statistical difference (two-sided exact
binomial test, p-value ≥ 0.10) for any population,
with the exception of the “Asian Indian” population
(p-value = 0.02) (Table 1). However, the Asian Indian
frequency was determined from a single study of just
976 individuals [19], where American subjects self-
categorized into one of six ethnic groups. Thus, this
Asian Indian carrier frequency truly represents self-
identified Americans of Indian descent, not a random
sample of individuals from the Indian subcontinent.
Each of our exact confidence intervals for the carrier
frequencies, including the Asian Indian subjects, over-
lapped with the published intervals.
Discussion
We developed and validated a computational protocol to
perform SMA carrier screening on individual exome se-
quence data. Our protocol eliminates the need to test
for SMA in a process distinct from all other carrier tests
that can be multiplexed in a single targeted gene panel.
Previous sequencing methods were restricted by their in-
ability to differentiate between the SMN1 and SMN2
gene paralogs [15]. We overcome this limitation by fo-
cusing on three nucleotide positions that are unique to
each gene.
We apply a Bayesian model to compute the probability
that a given individual is an SMA carrier given his or
her sequencing data at these loci. For each subject, we
measure his or her actual carrier probability on a con-
tinuous scale. In this way, we have a precise quantifica-
tion of carrier risk, which can lead to a more specific
prediction of affected progeny for any given couple.
We tested our technique on healthy volunteers and
samples with known carrier status from the Coriell
repository. Our sequencing and qPCR based results for
these samples led to identical conclusions; all likely
carriers (or non-carriers) by one method were carriers
(or not) by the other. We analyzed two carriers who
have a 1:1 ratio of SMN1 to SMN2 reads. These individ-
uals have one copy each of SMN1 and SMN2, yet their
SMN1:SMN2 reads ratio is no different than if they had
two copies each of SMN1 and SMN2 (or three, four,
etc.) and were not carriers. Nevertheless, we calculated a
high carrier probability for both of these subjects be-
cause our method scales SMN1 reads relative to several
“housekeeping” genes.
We also identified a carrier among our non-SMA
diseased control samples. This subject has been diagnosed
with SMAX1, and is not listed as an SMA carrier in
the Coriell database. However, according to both our
method and the MLPA analysis, he is an SMA carrier.
This is a crucial characteristic and should be added
to his public profile. Because he is an SMA carrier,
there is some chance that his SMAX1 affected family
members have been misdiagnosed and may actually
have SMA.
To demonstrate the utility of our method, we deter-
mined the carrier status of 2,501 subjects from the Phase
3 release of the 1000 Genomes Project based on only
their available sequencing data. These individuals repre-
sent a diverse global sample of adults without severe
pediatric disease, and their SMA carrier status was pre-
viously unknown. The majority of these samples are not
readily available for a wet lab carrier detection method; a
DNA-seq method is the only way to determine their
SMA carrier status. Our method is able to assign all sub-
jects in this cohort a carrier probability from sequencing
data alone, regardless of coverage. This is one of the ad-
vantages of our method and a continuous carrier prob-
ability outcome. The sequencing-based carrier rates in
the 1KG3 data were no different from the consolidation
of several PCR-based experiments.
The coverage of SMN necessary to accurately deter-
mine carrier status is dependent upon the underlying
genotype of a given individual. For use of our method in
the clinic, we recommend a at least 350 SMN reads for
90 % sensitivity, with the caveat that 2:3 SMN1:SMN2
subjects may still have intermediate carrier probabilities
at this coverage. These individuals are relatively rare
(1-3 % of the general population) [16, 17], and have
an average carrier probability of only 0.295 at our
recommended coverage level based on our simulation.
Because our carrier probabilities and corresponding
credible intervals for π incorporate the uncertainty asso-
ciated with low coverage, samples with fewer than 350
SMN reads can still be analyzed by our method. These
low coverage samples will have carrier probabilities
closer to ½ (i.e., more uncertainty) and wider inter-
vals than if they had more reads, but for many geno-
types, this will not result in the reclassification of a
sample. In our analysis, four (5.6 %) of the volunteer
and Coriell samples and 1,085 (43.4 %) of the 1KG3
samples (including 91 of 109 of the “possible” car-
riers) did not meet the recommended coverage. For
the purpose of quantifying the carrier status of all
subjects given only the provided data at hand, we
(See figure on previous page.)
Fig. 4 Results from the MLPA analysis in 60 subjects. a. Carrier probability for each sample stratified by MLPA category. b. Ratio of SMN1 exon 7
to reference sample versus carrier probability for each sample. Vertical lines at 0.7 and 1.3 represent thresholds for copy number loss and gain,
respectively. In both (a) and (b), tan, black, and green points represent samples that have less than, equal, and more than two copies of SMN1
exon 7, respectively
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Fig. 5 Results for 1000 Genomes samples. a. Estimate of the scaled proportion of SMN reads that are from SMN1 versus the carrier probability for
each subject. b. 95 % Posterior (credible) intervals for π are plotted for subjects with the lowest 200 estimates of π. In both (a) and (b), subjects
are colored and labeled under the same criteria as in Fig. 3
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included everyone in our analysis, regardless of
coverage.
As with existing SMA carrier detection methods, our
approach cannot take into account haplotype phase nor
identify cis, or silent “2 + 0”, carriers (i.e., individuals
with at least two copies of SMN1 on one chr5, but no
SMN1 the other), without additional information [21].
About 2-5 % of SMA carriers and about 1/800 individ-
uals have the 2 + 0 genotype [36–38]. Our method could
be extended to utilize distinct population polymor-
phisms to detect these carriers (e.g., in Ashkenazi Jews
[39]). Further, neither our method nor existing methods
can be used to prevent progeny with de novo mutations,
which occur in approximately 2 % of SMA cases [10, 40].
Conclusions
DNA sequencing has become the preferred tool for rec-
ognizing disease-causing variants throughout the gen-
ome. Large, multi-gene targeted sequencing panels are
the future of clinical carrier testing [41], and there is a
critical need for a comprehensive NGS test that includes
SMA carrier detection. The protocol presented here
should be implemented as part of broad genetic sequen-
cing screening tests to concurrently assess carrier risk
for multiple Mendelian diseases with only NGS data.
Without the extra step of qPCR, our approach is the
sole process that exclusively utilizes DNA-seq output to
measure the likelihood of an SMA carrier.
Availability of supporting data
Read counts at the loci of interest in SMN1 and SMN2
for all volunteer samples can be found in Additional file
7: Table S5.
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pObs (95 % exact CI)
Published carrier
frequency, p0 (95 % CI)
P-value
(H0: pObs = p0)
Caucasian (CEU, FIN, GBR, IBS, TSI) 503 13 0.026 (0.014 , 0.044) 0.022 (0.020, 0.024) 0.543
Black (ACB, ASW, ESN, GWD, LWK, MSL, YRI) 661 4 0.006 (0.002, 0.015) 0.014 (0.009, 0.018) 0.095
Asian (CDX, CHB, CHS, JPT, KHV) 502 6 0.012 (0.004, 0.026) 0.020 (0.016, 0.024) 0.261
Hispanic (MXL, PUR, CLM) 261 6 0.023 (0.009, 0.049) 0.012 (0.006, 0.017) 0.140
Asian Indian (GIH, ITU, STU, BEB, PJL) 489 3 0.006 (0.001, 0.018) 0.020 (0.010, 0.029) 0.022
All 2501 36 0.01 (0.010, 0.020) 0.019 (0.018, 0.020) 0.138
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